Paediatric embryonic brain tumours: Biological and clinical relevance of molecular genetic abnormalities

European Journal of Cancer

Volumn 38, Issue 5, 2002, Pages 675-685

  Gilbertson, R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Embryonal brain tumours; Molecular genetics; Paediatric

Indexed keywords

ARTICLE; BRAIN DYSFUNCTION; BRAIN TUMOR; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CHROMOSOME ABERRATION; DISEASE COURSE; GENETIC DISORDER; HISTOLOGY; HUMAN; MEDULLOBLASTOMA; MOLECULAR GENETICS; MORBIDITY; MORTALITY; ONCOLOGY; PRIORITY JOURNAL; REDUCTION; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; CHROMOSOME ABERRATIONS; HUMANS; MEDULLOBLASTOMA; NEOPLASMS, GERM CELL AND EMBRYONAL; SIGNAL TRANSDUCTION;

EID: 0036204622     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00315-X     Document Type: Article

References (112)

1. Embryonal central neuroepithelial tumours and their differentiating potential
2. Embryonal central neuroepithelial tumours: Current concepts and future challenges
3. Medulloblastoma
4. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: Evidence for a medulloblastoma subtype derived from the external granule cell layer
5. The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumours
6. Prognostic significance of molecular genetic markers in childhood brain tumours
7. Prognostic implications of chromosome 17p deletions in human medulloblastoma
8. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma
9. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumours (medulloblastomas) of the central nervous system
10. High-resolution mapping of chromosome arm 17p in childhood primitive neuroectodermal tumours reveals a common chromosomal disruption within the Smith-Magenis region, an unstable chromosome band 17p11.2
11. Molecular analysis of childhood primitive neuroectodermal tumours defines markers associated with poor clinical outcome
12. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation
13. Physical mapping of chromosome 17p13.3 in the region of a putitive tumour supressor gene important in medulloblastoma
14. Deletion mapping on chromosome 17p in medulloblastoma
15. Infrequent p53 gene mutations in medulloblastoma
16. Absence of p53 mutations in childhood central nervous system primitive neuroectodermal tumours
17. p53 mutations and mdm2 gene amplification are uncommon in medulloblastoma
18. Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours
19. Chromosomal analysis of brain tumours in childhood
20. Mapping of chromosomal gains and losses in primitive neuroectodermal tumours by comparative genomic hybridization
21. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridisation
22. Oncogene amplification in paediatric brain tumours
23. Comparative genomic hybridisation detects recurrent imbalances in central nervous system primitive neuroectodermal tumours in children
24. Comparative genomic hybridisation and histological variation in primitive neuroectodermal tumours
25. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumour with c-myc amplification
26. Prognostic implications of chromosome 17p deletions in human medulloblastoma
27. C-MYC expression in medulloblastoma and its prognostic value
28. Chromosomal characteristics of childhood brain tumours
29. Cytogenetic analysis of 120 primary paediatric brain tumours and literature review
30. Reduction to heterozygosity and gene amplification in central nervous system primitive neuroectodermal tumours of childhood
31. Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumours
32. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumours
33. Transducing Hedgehog: The story so far
34. The hedgehog signaling pathway in tumourigenesis and development
35. Gli proteins and Hedgehog signaling: Development and cancer
36. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog
37. Local control of granule cell generation by cerebellar Purkinje cells
38. Altered neural cell fates and medulloblastoma in mouse patched mutants
39. Location of gene for Gorlins syndrome
40. Localisation of the gene for nevoid basal cell carcinoma syndrome
41. Mutations of the human homologue of Drosophila patched in the nevoid basal cell carcinoma syndrome
42. Human homolog of patched, a candidate gene for the basal cell naevus syndrome
43. Sporadic medulloblastomas contain PTCH mutations
44. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumours of the central nervous system
45. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched
46. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours
47. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumours of the central nervous system
48. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma
49. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched
50. Basal cell carcinomas in mice overexpressing sonic hedgehog
51. Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors
52. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma
53. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine
54. Neurotrophic factors and their receptors
55. Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system
56. The p75 neurotrophin receptor and neuronal apoptosis
57. A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth
58. Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor
59. Neurotrophin-4/5 (NT-4/5) and brain-derived neurotrophic factor (BDNF) act at later stages of cerebellar granule cell differentiation
60. Differential expression of brain-derived neurotrophic factor, neurotrophin-3, and low-affinity nerve growth factor receptor during the postnatal development of the rat cerebellar system
61. TrkB and TrkC neurotrophin receptors cooperate in promoting survival of hippocampal and cerebellar granule neurons
62. Neurotrophin-3 controls proliferation of granular precursors as well as survival of mature granule neurons in the developing rat cerebellum
63. Neurotrophin-3 is required for proper cerebellar development
64. Cerebellar pathology in BDNF-/- mice: The classic view of neurotrophins is changing
65. Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors
66. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas
67. A novel apoptotic pathway induced by nerve growth factor-mediated TrkA activation in medulloblastoma
68. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma
69. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumours
70. Neuregulins and their receptors: A versitile signaling module in organogenesis and oncogenesis
71. The ErbB signaling network: Receptor heterodimerisation in development and cancer
72. A hierarhical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor
73. ErbB-2, the preffered heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
74. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2
75. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases
76. Cooperative signaling between alpha(6)beta(4) integrin and ErbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion
77. Central nervous system neuronal migration
78. Requirement of neuregulin receptor erbB2 in neural and cardiac development
79. ErbB3 is required for normal cerebellar and cardiac development: A comparison with ErbB2- and heregulin-deficient mice
80. Abberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
81. Multiple essential functions of neuregulin in development
82. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation
83. Distribution of neuregulin-1 (nrg1) and erbB4 transcripts in embryonic chick hindbrain
84. Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma
85. Expression of receptors for neuregulins, ErbB2, ErbB3 and ErbB4, in developing mouse cerebellum
86. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
87. Brain neurons and glial cells express Neu differentiation factor/heregulin: A survival factor for astrocytes
88. Opposing actions of the EGF family and opioids: Heparin binding-epidermal growth factor (HB-EGF) protects mouse cerebellar neuroblasts against the antiproliferative effect of morphine
89. Neuregulin and erbB receptors play a critical role in neuronal migration
90. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma
91. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
92. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children
93. Novel ErbB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma
94. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
95. Beta-catenin signaling and cancer
96. Roles of Wnt proteins in neural development and maintenance
97. High levels of expression of the tumour suppressor gene APC during development of the rat central nervous system
98. Brain tumour-polyposis syndrome: Two genetic diseases?
99. The molecular basis of Turcot's syndrome
100. Germ-line and somatic mutations of the APC gene in patients with Turcot syndrome and analysis of APC mutations in brain tumours
101. The APC gene in Turcot's syndrome
102. Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma
103. Sporadic medulloblastomas contain oncogenic beta-catenin mutations
104. APC mutations in sporadic medulloblastomas
105. Atypical teratoid/rhabdoid tumour
106. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations
107. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
108. Familial posterior fossa brain tumours of infancy secondary to germline mutation of the hSNF5 gene
109. Mutations of the hSNF5/INI1 gene in renal rhabdoid tumours with second primary brain tumours
110. Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumour and renal rhabdoid tumour
111. ATP-dependent chromatin remodelling: SWI/SNF and Co. are on the job